nature portfolio

Corresponding author(s):	BRYAN KILLINGER
Last updated by author(s):	2-7-2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

<u> </u>			
≤ t	-at	·ict	ICC

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed	
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statis	tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.
	A descript	tion of all covariates tested
	A descript	tion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)	
	For null h	ypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted ses as exact values whenever suitable.
\boxtimes	For Bayes	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates	of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftware an	d code
Poli	cy information	about <u>availability of computer code</u>
Da	ata collection	NIKON ELEMENTS SOFTWARE WAS USED TO QUANTIFY PATHOLOGY.
Da	ata analysis	GRAPHPAD PRISM, R HEATMAP PACKAGE, CYTOSCAPE, GPROFILER, STRING, AND NIKON ELEMENTS SOFTWARE.
Forn	nanuscripts utilizing	g custom algorithms or software that are central to the research but not vet described in published literature, software must be made available to editors and

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our $\underline{\text{policy}}$

All data will be available upon request. Mass spectrometry raw data files are available via PRIDE data repository under the identifier PXD 045437. Detailed protocols for detection of seeded pathology and BAR are made publicly available through dx.doi.org/10.17504/protocols.io.5jyl8pzzdg2w/v1 and dx.doi.org/10.17504/protocols.io.14egn3qq6l5d/v1, respectively.

Research inv	volving hu	man participants, their data, or biological material
Policy information	about studies v	vith

Antibodies

Antibodies used

EP1536Y (Abcam), Clone 42/α-Synuclein BD Transduction Laboratories.

We have conducted extensive validation of antibody EP1536Y (Abcam). We have used, preabsorbtion, alpha-synuclien knockout mice, primary delete, and western blot studies to validate our use of this antibody.

Animals and other research organisms

Policy information about <u>studies involving animals</u>; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in Research</u>

Laboratory animals	57BL/6N-Gba1tm1.1Mjff/J mice (GBA1 D409V KI) and C57BL/6 WT mice from jackson labs.
Wild animals	NA
Reporting on sex	Both sex were used. But no sex specific effects were hypothesized.
Field-collected samples	NA
Ethics oversight	Animal maintenance and experiments were performed in accordance with the National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee of the Rush University Medical Center (Chicago, IL)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about <u>clinical studies</u>

 $All \ manuscripts \ should \ comply \ with \ the \ ICMJE \ \underline{guidelines \ for \ publication \ of \ clinical \ research} \ and \ a \ completed \ \underline{CONSORT \ checklist} \ must \ be \ included \ with \ all \ submissions.$

Clinical trial registration	na
Study protocol	na
Data collection	na
Outcomes	na

Plants

Seed stocks	(NA
Novel plant genotypes	NA
Authentication	NA